Add to a list

Inactive Instrument

NEOPROBE Stock OTC Bulletin Board

NEOP

US6405181065

Biotechnology & Medical Research

OTC Markets Traded

End-of-day quote OTC Bulletin Board
- ^USD	-

30/01	Motion for Asset Sale Approved for Navidea Biopharmaceuticals, Inc.	CI
27/01	Notice of Asset Purchase Agreement Filed by Navidea Biopharmaceuticals, Inc.	CI

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Companyâ€™s business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	5.52M 4.78M 4.48M 4.09M 7.68M 526M 7.8M 52.7M 20.6M 264M 20.72M 20.27M 879M	P/E 2021	-2.5x	P/E 2022	-0.38x
Enterprise Value	5.96M 5.16M 4.84M 4.41M 8.3M 568M 8.42M 56.9M 22.24M 285M 22.38M 21.89M 949M	EV / Sales 2021	50.2x	EV / Sales 2022	110x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

30/01	Motion for Asset Sale Approved for Navidea Biopharmaceuticals, Inc.	CI
27/01	Notice of Asset Purchase Agreement Filed by Navidea Biopharmaceuticals, Inc.	CI
23/01	Notice of Successful Bidder Filed by Navidea Biopharmaceuticals, Inc.	CI
30/12	Reorganization Plan Filed by Navidea Biopharmaceuticals, Inc.	CI
11/12	Bidding Procedure Approved for Navidea Biopharmaceuticals, Inc.	CI
24/11	Motion for Asset Sale Filed by Navidea Biopharmaceuticals, Inc.	CI
07/11	Motion for Case Dismissal or Order Limiting the Debtor-in-Possession?s Powers, Equitably Subordinating Certain Claims or Expanding the Subchapter V Trustee?s Powers Withdrawn for Navidea Biopharmaceuticals, Inc.	CI
07/11	Final DIP Financing Approved for Navidea Biopharmaceuticals, Inc.	CI
03/11	Motion for Case Dismissal or Order Limiting the Debtor-in-Possession?s Powers, Equitably Subordinating Certain Claims or Expanding the Subchapter V Trustee?s Powers Filed for Navidea Biopharmaceuticals, Inc.	CI
09/10/25	Interim DIP Financing Approved for Navidea Biopharmaceuticals, Inc.	CI
09/10/25	Navidea Biopharmaceuticals files for bankruptcy	RE
02/10/25	Navidea Biopharmaceuticals, Inc. Filed for Bankruptcy	CI
04/07/24	Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024	CI

10/10/25	Navidea Biopharmaceuticals Inc. Files for Bankruptcy	AQ
05/12/23	Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release	AQ
15/11/23	Navidea: Q3 Earnings Snapshot	AQ
06/10/23	Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock	BU
10/08/23	Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel	BU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	+1.54%	+1.59%	+4.54%	+16.47%	48.72B
REVOLUTION MEDICINES, INC.	-0.06%	+3.79%	+469.18%	+584.35%	43.99B
BEONE MEDICINES AG	-0.32%	+8.67%	+16.55%	+75.58%	40.82B
IQVIA HOLDINGS INC.	+0.46%	+4.88%	+28.15%	+10.75%	39.79B
CELLTRION, INC.	-4.04%	+6.15%	+23.03%	+48.00%	32.7B
MEDPACE HOLDINGS, INC.	-0.61%	+1.27%	+26.59%	+123.04%	16.66B
ASCENDIS PHARMA A/S	-3.32%	-1.28%	-	-	16.84B
EUROFINS SCIENTIFIC SE	+1.09%	+0.74%	+5.39%	+22.10%	13.95B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.45%	+7.35%	+83.89%	+31.41%	13.58B
Average	-0.52%	+3.96%	+82.16%	+113.96%	29.67B
Weighted average by Cap.	-0.32%	+3.93%	+100.19%	+137.40%

	2021	2022
Net sales	532K 461K 431K 394K 740K 50.7M 751K 5.07M 1.98M 25.38M 2M 1.95M 84.64M	65.65K 56.88K 53.29K 48.61K 91.39K 6.26M 92.79K 627K 245K 3.14M 246K 241K 10.45M
Net income	-11.73M -10.16M -9.52M -8.69M -16.33M -1.12B -16.58M -112M -43.78M -560M -44.04M -43.09M -1.87B	-15.18M -13.15M -12.32M -11.24M -21.13M -1.45B -21.45M -145M -56.64M -725M -56.98M -55.75M -2.42B
Net Debt	-3.48M -3.02M -2.83M -2.58M -4.85M -332M -4.92M -33.24M -12.99M -166M -13.07M -12.79M -554M	440K 381K 357K 326K 612K 41.94M 622K 4.2M 1.64M 21M 1.65M 1.62M 70.03M

NEOPROBE Stock OTC Bulletin Board

Stocks

NEOP

US6405181065

Biotechnology & Medical Research

Valuation: NEOPROBE

Latest news : NEOPROBE

Press Releases: NEOPROBE

Managers and Directors: NEOPROBE

Other Biotechnology & Medical Research

Financials

Company Profile